(VIANEWS) – National Oilwell Varco (NOV), FTI Consulting (FCN), Inter Parfums (IPAR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. National Oilwell Varco (NOV)
11.3% sales growth and 9.32% return on equity
NOV Inc. designs, constructs, manufactures, and sells systems, components, and products for oil and gas drilling and production, and industrial and renewable energy sectors worldwide. The company operates through three segments: Wellbore Technologies, Completion & Production Solutions, and Rig Technologies. It provides solids control and waste management equipment and services; portable power generation products; drill and wired pipes; drilling optimization and automation services; tubular inspection, repair, and coating services; instrumentation; measuring and monitoring services; downhole and fishing tools; steerable technologies; and drill bits. The company also offers equipment and technologies for hydraulic fracture stimulation, including downhole multistage fracturing tools, pressure pumping trucks, blenders, sanders, hydration and injection units, flowline, and manifolds; coiled tubing units, and wireline units and tools; connections and liner hangers; onshore production consists of composite pipe, surface transfer and progressive cavity pumps, and artificial lift systems; and offshore production, such as floating production systems and subsea production technologies, as well as manufactures industrial pumps and mixers. In addition, it provides substructures, derricks, and masts; cranes; jacking systems; pipe lifting, racking, rotating, and assembly systems; mud pumps; pressure control equipment; drives and generators; rig instrumentation and control systems; mooring, anchor, and deck handling machinery; equipment components for offshore wind construction vessels; and pipelay and construction systems. Further, the company offers spare parts, repair, and rentals as well as comprehensive remote equipment monitoring, technical support, field service, and customer training. The company was formerly known as National Oilwell Varco, Inc. and changed its name to NOV Inc. in January 2021. NOV Inc. was founded in 1862 and is based in Houston, Texas.
Earnings Per Share
As for profitability, National Oilwell Varco has a trailing twelve months EPS of $1.26.
PE Ratio
National Oilwell Varco has a trailing twelve months price to earnings ratio of 14.8. Meaning, the purchaser of the share is investing $14.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.32%.
Volume
Today’s last reported volume for National Oilwell Varco is 2471980 which is 29.58% below its average volume of 3510800.
2. FTI Consulting (FCN)
10.1% sales growth and 13.72% return on equity
FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company operates through five segments: Corporate Finance & Restructuring, Forensic and Litigation Consulting, Economic Consulting, Technology, and Strategic Communications. Its Corporate Finance & Restructuring segment provides business transformation, transactions, and turnaround and restructuring services. The company's Forensic and Litigation Consulting segment offers. construction and environmental solution, data and analytics, dispute, health solution, and risk and investigation services. Its Economic Consulting segment provides. antitrust and competition economic, financial economic, and international arbitration services. The company's Technology segment offers corporate legal operation; e-discovery and expertise; and information governance, privacy, and security services. Its Strategic Communications segment provides corporate reputation, financial communication, and public affairs services. The company serves aerospace and defense, agriculture, airlines and aviation, automotive and industrial, construction, energy, power and products, environmental solutions, financial services, healthcare and life sciences, hospitality, gaming and leisure, insurance, mining, private equity, public sector, real estate, retail and consumer products, telecom, media and technology, and transportation and logistics industries. The company was founded in 1982 and is headquartered in Washington, District of Columbia.
Earnings Per Share
As for profitability, FTI Consulting has a trailing twelve months EPS of $6.76.
PE Ratio
FTI Consulting has a trailing twelve months price to earnings ratio of 32.92. Meaning, the purchaser of the share is investing $32.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.72%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FTI Consulting’s EBITDA is 2.45.
Sales Growth
FTI Consulting’s sales growth is 7.2% for the current quarter and 10.1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 5.3% and 38.1%, respectively.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 2.46%.
3. Inter Parfums (IPAR)
9.8% sales growth and 24.45% return on equity
Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally. The company operates in two segments, European Based Operations and United States Based Operations. It offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade New York, Lanvin, Montblanc, Paul Smith, Repetto, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, bebe, Dunhill, Hollister, French Connection, Graff, GUESS, Lily Aldridge, MCM, Bella Vita, and Oscar de la Renta brand names, as well as under the Intimate and Aziza names. It sells its products to department stores, specialty stores, duty free shops, beauty retailers, and domestic and international wholesalers, and distributors, as well as through e-commerce. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Inter Parfums has a trailing twelve months EPS of $4.94.
PE Ratio
Inter Parfums has a trailing twelve months price to earnings ratio of 25.11. Meaning, the purchaser of the share is investing $25.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.45%.
Sales Growth
Inter Parfums’s sales growth is 4.1% for the present quarter and 9.8% for the next.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Dec 13, 2023, the estimated forward annual dividend rate is 2.5 and the estimated forward annual dividend yield is 2%.
4. ICON plc (ICLR)
6.5% sales growth and 5.97% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $6.21.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 43.48. Meaning, the purchaser of the share is investing $43.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.97%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 10.5% and 19.7%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ICON plc’s EBITDA is 3.25.
Yearly Top and Bottom Value
ICON plc’s stock is valued at $270.02 at 04:22 EST, under its 52-week high of $273.53 and way above its 52-week low of $181.92.
Sales Growth
ICON plc’s sales growth is 6.6% for the ongoing quarter and 6.5% for the next.
